Top 10 Deals of 2022: Overview

Amboy Street Ventures’ Top 10 Deals of 2022 series looks at this year’s four major M&A trends in the women’s health and sexual health space.

What are the potential exit paths for women’s health and sexual health companies?

As we kick-off our second annual “Top 10 Deals of the Year” series, we dive into the key exit trends of 2022 in the women’s health and sexual health space.

While the ten year bull market came to a close and IPOs and SPACs seemed to have disappeared, the women’s health and sexual health category still boasted strong exits in 2022 – all thanks to mergers & acquisitions! The massive exits this year further support the recession-resistant nature of the women’s health and sexual health market.

Our 2022 top 10 deals can be categorized into four major M&A trends:

1) Consumer packaged goods (CPG) conglomerates acquired women’s health and sexual health companies to fill gaps in their brand portfolios (blog here),

2) Late stage venture backed companies grew through strategic acquisitions (blog here),

3) Mature healthcare companies decided to buy instead of build in order to innovate (blog here), and

4) PE funds dipped their toes in women’s health and sexual health acquisitions (blog here).

Stay tuned over the next few weeks as Amboy Street reveals the women’s health and sexual health top 10 deals of 2022 within these four M&A trends.

Finally, as it is election day – the future of women’s reproductive rights is in our hands. We hope to see you at the polls!

Continue Reading

Top 10 Deals of 2026: ŌURA to Acquire Counsel Health for $625M

Every year, Amboy Street highlights the top 10 transactions in women’s health. The next deal in this year’s series is ŌURA’s agreement to acquire Counsel Health, an AI-native primary care company, for $625 million in cash.

Top 10 Deals of 2026: Ferring to Acquire Gameto for up to $1.38B

Every year, Amboy Street highlights the top 10 transactions in women’s health. The splashy news of the week, and the next blog in our series, is Ferring Pharmaceuticals’ agreement to acquire Gameto, a cell-engineering company reimagining IVF, in a deal worth up to $1.38 billion.

Top 10 Deals of 2026: Sun Pharma to Acquire Organon for $11.75B

Every year, Amboy Street highlights the top 10 transactions in women’s health. This year’s series starts with one of the largest women’s health mergers in history.

Top 10 Deals of 2026: ŌURA to Acquire Counsel Health for $625M

Every year, Amboy Street highlights the top 10 transactions in women’s health. The next deal in this year’s series is ŌURA’s agreement to acquire Counsel Health, an AI-native primary care company, for $625 million in cash.

Top 10 Deals of 2026: Ferring to Acquire Gameto for up to $1.38B

Every year, Amboy Street highlights the top 10 transactions in women’s health. The splashy news of the week, and the next blog in our series, is Ferring Pharmaceuticals’ agreement to acquire Gameto, a cell-engineering company reimagining IVF, in a deal worth up to $1.38 billion.

Fast track our industry.
Get in touch today.